TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms

被引:0
|
作者
Fu, Zhanqi [1 ,2 ,3 ]
Yuan, Yuan [1 ,2 ,3 ]
机构
[1] China Med Univ, Hosp 1, Tumor Etiol & Screening Dept, Canc Inst & Gen Surg, 155 Nanjing Bei St, Shenyang 110001, Peoples R China
[2] China Med Univ, Liaoning Educ Dept, Key Lab Canc Etiol & Prevent, Hosp 1, Shenyang 110001, Peoples R China
[3] China Med Univ, Hosp 1, Key Lab GI Canc Etiol & Prevent Liaoning Prov, Shenyang 110001, Peoples R China
关键词
TNFAIP2; Cancer; Nanotube formation; Pharmacology; Drug therapy; SQUAMOUS-CELL CARCINOMA; TUNNELING NANOTUBES; PROMOTES; ALPHA; IDENTIFICATION; METASTASIS; GENE; B94;
D O I
10.1016/j.phrs.2024.107199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
TNF alpha-induced protein 2 (TNFAIP2), upregulated under TNF alpha stimulation, was initially thought to participate in angiogenesis. Still, more and more studies have found that TNFAIP2 plays multiple roles in various physiological and pathological scenarios. The representative functions of TNFAIP2 include motivating the inflammatory response, promoting angiogenesis, facilitating cell proliferation, adhesion, migration, and inducing tunnel nanotube formation. The expression of TNFAIP2 is abnormal in most cancers and can enhance drug resistance in cancer cells. The increasingly recognized significance of TNFAIP2 has been attracting growing attention in recent years. This review focuses on elucidating the relationship between TNFAIP2 and oncogenesis, as well as the latest research advancements in the pharmacological targeting of TNFAIP2, aiming to guide forthcoming endeavors in developing pharmacological agents targeted at modulating TNFAIP2.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions
    Eller-Smith, Olivia C.
    Nicol, Andrea L.
    Christianson, Julie A.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
  • [22] Osteopontin: an emerging therapeutic target for anticancer therapy
    Jain, Shalini
    Chakraborty, Goutam
    Bulbule, Anuradha
    Kaur, Rajinder
    Kundu, Gopal C.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (01) : 81 - 90
  • [23] TNFAIP2 is required for growth and migration of ovarian cancer cells and functions to regulate trafficking of receptor tyrosine kinases
    Duraisamy, Sekhar
    Levanon, Keren
    Adelmant, Guillaume
    Piao, Huiying
    Liu, Joyce
    Matulonis, Ursula
    Hirsch, Michelle
    Marto, Jarrod A.
    Drapkin, Ronny
    CLINICAL CANCER RESEARCH, 2013, 19
  • [24] The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
    Wang, Ziyi
    Jia, Renxiang
    Wang, Linlin
    Yang, Qiwei
    Hu, Xiaohai
    Fu, Qiang
    Zhang, Xinyu
    Li, Wenya
    Ren, Yi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy
    Jiang, Jiangling
    Wang, Jijun
    Li, Chunbo
    NEUROSCIENCE BULLETIN, 2017, 33 (03) : 339 - 347
  • [26] Ferroptosis: An emerging therapeutic target for oral cancer
    Balachander, Kannan
    Paramasivam, Arumugam
    ORAL ONCOLOGY, 2022, 131
  • [27] Autophagy in Cervical Cancer: An Emerging Therapeutic Target
    Pandey, Saumya
    Chandravati
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4867 - 4871
  • [28] Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy
    Jiangling Jiang
    Jijun Wang
    Chunbo Li
    Neuroscience Bulletin, 2017, 33 : 339 - 347
  • [29] Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy
    Jiangling Jiang
    Jijun Wang
    Chunbo Li
    Neuroscience Bulletin, 2017, 33 (03) : 339 - 347
  • [30] Podoplanin: An emerging cancer biomarker and therapeutic target
    Krishnan, Harini
    Rayes, Julie
    Miyashita, Tomoyuki
    Ishii, Genichiro
    Retzbach, Edward P.
    Sheehan, Stephanie A.
    Takemoto, Ai
    Chang, Yao-Wen
    Yoneda, Kazue
    Asai, Jun
    Jensen, Lasse
    Chalise, Lushun
    Natsume, Atsushi
    Goldberg, Gary S.
    CANCER SCIENCE, 2018, 109 (05) : 1292 - 1299